ASX Announcements

Dec 2020
Dec 24th, 2020
Change in substantial holding
Dec 22nd, 2020
VIRALEZE COVID-19 nasal spray study to commence in January
Dec 22nd, 2020
Change in substantial holding
Dec 10th, 2020
VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21

Nov 2020
Nov 24th, 2020
Change in Director's Interest Notice - J Fairley
Nov 24th, 2020
Appendix 3G
Nov 20th, 2020
2020 AGM Results
Nov 20th, 2020
Retirement of non-executive director Richard Hazleton
Nov 20th, 2020
AGM Chairman address and CEO presentation
Nov 19th, 2020
SPL7013 shows potent antiviral activity in RSV
Nov 13th, 2020
Appendix 3G
Nov 4th, 2020
Change in Director's Interest Notice - R Thomas
Nov 4th, 2020
Change in Director's Interest Notice - J Fairley
Nov 4th, 2020
Change in Director's Interest Notice - P Turvey
Nov 4th, 2020
Appendix 2A

Oct 2020
Oct 30th, 2020
Appendix 2A
Oct 30th, 2020
Quarterly Cashflow and Activities Report
Oct 29th, 2020
Completion of Placement and SPP raises $48.9M in total
Oct 21st, 2020
Starpharma receives $5.7M R&D tax incentive refund
Oct 20th, 2020
Shareholder Update October 2020
Oct 19th, 2020
Notice of Annual General Meeting/Proxy Form
Oct 9th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 8th, 2020
Change in substantial holding
Oct 7th, 2020
Share Purchase Plan offer document
Oct 6th, 2020
Appendix 2A
Oct 6th, 2020
Cleansing Notice
Oct 5th, 2020
Change in Director's Interest Notice - R Thomas
Oct 5th, 2020
Change in Director's Interest Notice - J Fairley

Sep 2020
Sep 30th, 2020
Investor Presentation
Sep 30th, 2020
Starpharma completes oversubscribed A$45M placement
Sep 30th, 2020
Proposed issue of Securities
Sep 28th, 2020
Trading halt
Sep 25th, 2020
VivaGel® BV secures TGA approval for prevention of BV
Sep 23rd, 2020
2020 Annual General Meeting
Sep 23rd, 2020
Appendix 2A
Sep 18th, 2020
Change in substantial holding
Sep 17th, 2020
Change in substantial holding
Sep 17th, 2020
Starpharma to present at OTCQX Life Sciences Investor Forum
Sep 14th, 2020
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Sep 3rd, 2020
Change in substantial holding
Sep 3rd, 2020
Starpharma awarded $1M MRFF funding for COVID-19 spray
Sep 1st, 2020
SPL creates slow release soluble DEP® remdesivir nanoparticle
Sep 1st, 2020
Change in substantial holding

Aug 2020
Aug 27th, 2020
Annual report and full year financial results
Aug 27th, 2020
Appendix 4G - Corporate Governance Statement
Aug 25th, 2020
SPL7013 nasal spray for COVID-19 – development update
Aug 17th, 2020
Starpharma signs new DEP® partnership with Chase Sun

Jul 2020
Jul 30th, 2020
DEP® docetaxel and gemcitabine combination trial commences
Jul 30th, 2020
Quarterly Cashflow and Activities Report
Jul 27th, 2020
AZD0466 trial opens MD Anderson Cancer Center as a site
Jul 9th, 2020
New Australian site opening for DEP® trials

Jun 2020
Jun 29th, 2020
DEP® irinotecan boosts immuno-oncology in colon cancer models
Jun 23rd, 2020
Multiple DEP® products showcased at AACR 2020
Jun 18th, 2020
Starpharma to present at OTCQX Virtual Investor Conference
Jun 17th, 2020
DEP® lutetium effective in human prostate cancer model
Jun 16th, 2020
VivaGel® BV launched in central and eastern European countries
Jun 16th, 2020
Notice of initial substantial holder

May 2020
May 26th, 2020
Notice of initial substantial holder
May 14th, 2020
Shareholder Update May 2020
May 7th, 2020
DEP® irinotecan phase 2 commences after positive phase 1 results
May 5th, 2020
Starpharma presents at Macquarie Australia Conference

Apr 2020
Apr 15th, 2020
SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)
Apr 7th, 2020
Quarterly Cashflow and Activity Report

Mar 2020
Mar 20th, 2020
Appendix 2A
Mar 4th, 2020
Okamoto licenses VivaGel® antiviral condom in Asian countries
Mar 2nd, 2020
Starpharma appoints David McIntyre and Appendix 3X

Feb 2020
Feb 24th, 2020
Interim Report and Half-Year Financial Results
Feb 13th, 2020
VivaGel BV launched in Asia
Feb 12th, 2020
David McIntyre appointed as non-executive director
Feb 11th, 2020
Starpharma receives US$3M milestone from AstraZeneca

Jan 2020
Jan 30th, 2020
Shareholder Update January 2020
Jan 29th, 2020
Quarterly Cashflow Report
Jan 24th, 2020
Appendix 3B

Dec 2019
Dec 30th, 2019
Commencement of phase 1 trial for AZD0466 utilising DEP®
Dec 16th, 2019
Starpharma receives $4.9M R&D tax incentive refund
Dec 10th, 2019
DEP® cabazitaxel progresses to phase 2 on positive results
Dec 4th, 2019
Appendix 3B
Dec 4th, 2019
Change in Director's Interest Notice - J Fairley

Nov 2019
Nov 21st, 2019
AGM Results
Nov 21st, 2019
AGM Chairman’s address and CEO’s presentation
Nov 20th, 2019
VivaGel® condom receives regulatory approval in Europe
Nov 19th, 2019
2019 AGM details
Nov 13th, 2019
UK launch of VivaGel® BV
Nov 12th, 2019
Notice of initial substantial holder

Oct 2019
Oct 31st, 2019
DEP® gemcitabine outperforms Gemzar® in human pancreatic cancer model
Oct 30th, 2019
Quarterly Cashflow Report
Oct 23rd, 2019
Ceasing to be a substantial holder
Oct 23rd, 2019
Change in substantial holding
Oct 18th, 2019
Notice of Annual General Meeting/Proxy Form
Oct 17th, 2019
Appendix 3B
Oct 8th, 2019
Starpharma to present at US Drug Delivery Conference
Oct 1st, 2019
Change in Director's Interest Notice - J Fairley
Oct 1st, 2019
Appendix 3B

Sep 2019
Sep 26th, 2019
FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466
Sep 24th, 2019
AGM Date Notification
Sep 12th, 2019
DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model
Sep 9th, 2019
Change in substantial holding
Sep 3rd, 2019
VivaGel® BV regulatory approvals continue in Asia

Aug 2019
Aug 29th, 2019
Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model
Aug 28th, 2019
Starpharma annual report and full year financial results
Aug 28th, 2019
Appendix 4G – Corporate Governance Statement
Aug 28th, 2019
Promising efficacy signals observed in ongoing DEP® trials, including DEP® cabazitaxel escalation phase
Aug 15th, 2019
First Asian Regulatory Approvals Received for VivaGel® BV
Aug 8th, 2019
Starpharma commences phase 1/2 DEP® irinotecan trial

Jul 2019
Jul 29th, 2019
Appendix 3B
Jul 16th, 2019
Quarterly Cashflow Report
Jul 1st, 2019
Shareholder Update July 2019

Jun 2019
Jun 27th, 2019
VivaGel® BV launched in Europe
Jun 20th, 2019
Starpharma presents at Macquarie Emerging Leaders Forum
Jun 12th, 2019
US patent granted for DEP Bcl2/xL inhibitor conjugates
Jun 4th, 2019
Okamoto launches VivaGel® condom in Japan
Jun 3rd, 2019
Starpharma signs second oncology agreement with AstraZeneca

May 2019
May 29th, 2019
Starpharma presents at UBS Healthcare Conference
May 24th, 2019
DEP irinotecan combination outperforms in refractory human colon cancer model
May 23rd, 2019
Regulatory progress for VivaGel BV in the US
May 7th, 2019
Starpharma to present at US Drug Delivery Conference
May 1st, 2019
Starpharma presents at Macquarie Australia Conference
May 1st, 2019
Notice of Ceasing to be Substantial Holder

Apr 2019
Apr 29th, 2019
Quarterly Cashflow Report
Apr 16th, 2019
First VivaGel BV launch globally in Australia by Aspen
Apr 11th, 2019
Starpharma meets with US FDA to discuss VivaGel® BV
Apr 3rd, 2019
Starpharma Investor Presentation to Goldman Sachs Conference

Mar 2019
Mar 19th, 2019
Appendix 3B
Mar 18th, 2019
Shareholder Update March 2019
Mar 12th, 2019
Starpharma receives $4.0M R&D tax incentive refund

Feb 2019
Feb 27th, 2019
Interim Report and Half-Yearly Financial Results
Feb 8th, 2019
Appendix 3B

Jan 2019
Jan 30th, 2019
Quarterly Cashflow Report
Jan 17th, 2019
Shareholder Update January 2019
Jan 14th, 2019
Notice of initial substantial holder
Jan 7th, 2019
SPL - Response to ASX Aware Letter
Jan 2nd, 2019
VivaGel® condom receives final regulatory approval in Japan

Dec 2018
Dec 28th, 2018
Change in Director's Interest Notice - J Fairley
Dec 28th, 2018
Change in Director's Interest Notice - P Turvey
Dec 28th, 2018
Change in Director's Interest Notice - R Thomas
Dec 27th, 2018
US FDA requests further data for VivaGel® BV approval
Dec 27th, 2018
Notice of Ceasing to be a Substantial Holder
Dec 20th, 2018
US VivaGel® BV licensed for A$142M milestones, plus royalties
Dec 12th, 2018
US patent granted for SPL7013 eye drops for conjunctivitis
Dec 11th, 2018
Change in Director's Interest Notice - J Fairley
Dec 11th, 2018
Appendix 3B
Dec 11th, 2018
Notice of initial substantial holder

Nov 2018
Nov 29th, 2018
2018 AGM Results
Nov 29th, 2018
AGM - Chairman address and CEO presentation
Nov 16th, 2018
DEP® docetaxel and DEP® cabazitaxel outperform in human pancreatic cancer model
Nov 5th, 2018
Appendix 3B

Oct 2018
Oct 26th, 2018
Notice of General Meeting/Proxy Form
Oct 26th, 2018
Quarterly Cashflow Report
Oct 17th, 2018
Starpharma Investor Presentation for Citi Conference
Oct 8th, 2018
Ceasing to be a substantial holder
Oct 5th, 2018
Change in Director's Interest Notice - J Fairley
Oct 5th, 2018
Appendix 3B
Oct 2nd, 2018
Notification of AGM date

Sep 2018
Sep 14th, 2018
Change in substantial holding
Sep 5th, 2018
DEP® irinotecan outperforms in pancreatic cancer model

Aug 2018
Aug 31st, 2018
AstraZeneca’s DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination
Aug 21st, 2018
Appendix 4G - Corporate Governance Statement
Aug 21st, 2018
Annual report and full year financial results

Jul 2018
Jul 17th, 2018
Quarterly Cashflow Report
Jul 9th, 2018
VivaGel® BV NDA advances to next stage of FDA review

Jun 2018
Jun 27th, 2018
Starpharma licenses VivaGel® BV to Mundipharma for Europe
Jun 6th, 2018
Change in substantial holding

May 2018
May 17th, 2018
Change in Director's Interest Notice - R Thomas
May 3rd, 2018
Mundipharma licenses Starpharma’s VivaGel® BV

Apr 2018
Apr 30th, 2018
Starpharma completes US New Drug Application for VivaGel BV
Apr 30th, 2018
Quarterly Cashflow Report
Apr 11th, 2018
Starpharma to present at OTCQX Virtual Investor Conference

Mar 2018
Mar 21st, 2018
Change in Director's Interest Notice - J Fairley
Mar 20th, 2018
Change in Director's Interest Notice - R Thomas
Mar 20th, 2018
Appendix 3B
Mar 15th, 2018
Change in Director's Interest Notice - R Thomas
Mar 12th, 2018
Change in Director's Interest Notice - P Turvey
Mar 12th, 2018
Change in Director's Interest Notice - J Fairley
Mar 5th, 2018
Change in Director's Interest Notice - R Thomas

Feb 2018
Feb 26th, 2018
Interim Report and Half-Yearly Financial Results
Feb 22nd, 2018
Starpharma receives $3.7M R&D tax incentive refund
Feb 19th, 2018
Shareholder Update February 2018

Jan 2018
Jan 31st, 2018
Starpharma to commence DEP® cabazitaxel phase 1/2 trial
Jan 29th, 2018
Appendix 3B
Jan 25th, 2018
Appendix 4C - Quarterly Cashflow Report

Dec 2017
Dec 21st, 2017
VivaGel® BV treatment clinical submission under rolling submission
Dec 11th, 2017
Change in Director's Interest Notice - J Fairley
Dec 11th, 2017
Appendix 3B
Dec 5th, 2017
Change in Director's Interest Notice - R Thomas

Nov 2017
Nov 29th, 2017
AGM Chairman's address and CEO presentation
Nov 29th, 2017
AGM Results
Nov 29th, 2017
Starpharma's amended Constitution
Nov 21st, 2017
NDA submission for VivaGel BV in the US
Nov 8th, 2017
Change in Director's Interest Notice - J Fairley

Oct 2017
Oct 31st, 2017
Change in Director's Interest Notice - R Thomas
Oct 27th, 2017
Notice of Annual General Meeting/Proxy Form
Oct 26th, 2017
Appendix 4C - Quarterly Cashflow Report
Oct 25th, 2017
VivaGel® BV granted marketing approval in Australia
Oct 18th, 2017
Shareholder Update October 2017
Oct 12th, 2017
Appendix 3B
Oct 9th, 2017
Starpharma and Peter Mac Cancer Centre awarded DEP® Grant
Oct 5th, 2017
Change in Director's Interest Notice - J Fairley
Oct 5th, 2017
Appendix 3B
Oct 2nd, 2017
Notification of AGM date

Sep 2017
Sep 28th, 2017
AstraZeneca presents first DEP® candidate as Bcl2-xL inhibitor
Sep 22nd, 2017
DEP® docetaxel positive phase 1 results; phase 2 commences

Aug 2017
Aug 28th, 2017
Annual report and full year financial results
Aug 28th, 2017
Appendix 4G - Corporate Governance Statement
Aug 24th, 2017
Starpharma to present at Finance News Network Investor Event
Aug 21st, 2017
Appendix 3B
Aug 9th, 2017
Starpharma and Monash awarded STEM+ Business Fellowships
Aug 7th, 2017
Successful VivaGel Phase 3 results and NDA planned for rBV

Jul 2017
Jul 19th, 2017
Appendix 4C - Quarterly Cashflow Report
Jul 4th, 2017
VivaGel® BV phase 3 results timing and commercialisation
Jul 4th, 2017
Shareholder Update July 2017

Jun 2017
Jun 14th, 2017
Starpharma sells Agrochemicals business to Agrium for $35M
Jun 14th, 2017
Sale of Agrochemicals Business Investor Presentation
Jun 14th, 2017
Appendix 3B
Jun 6th, 2017
DEP® irinotecan outperforms irinotecan in multiple cancer models
Jun 2nd, 2017
Starpharma receives DEP® milestone from AstraZeneca

Apr 2017
Apr 28th, 2017
Appendix 4C - Quarterly Cashflow Report
Apr 20th, 2017
AstraZeneca DEP® candidate advance triggers milestone to Starpharma
Apr 12th, 2017
Ansell launches VivaGel® condom in Canada

Mar 2017
Mar 30th, 2017
VivaGel® BV phase 3 trials for prevention of BV completed

Feb 2017
Feb 27th, 2017
Interim Report and Half-Yearly Financial Results

Jan 2017
Jan 31st, 2017
Appendix 4C - Quarterly Cashflow Report
Jan 25th, 2017
Appendix 3B
Jan 19th, 2017
Shareholder Update January 2017
Jan 12th, 2017
VivaGel® BV granted QIDP and Fast Track designation by US FDA

Dec 2016
Dec 22nd, 2016
Starpharma receives $3.5M R&D tax incentive refund
Dec 5th, 2016
Change in Director's Interest Notice - R Thomas
Dec 5th, 2016
Appendix 3B
Dec 5th, 2016
Change in Director's Interest Notice - J Fairley

Nov 2016
Nov 29th, 2016
2016 AGM Results
Nov 28th, 2016
Starpharma signs license for VivaGel Condom in Iran
Nov 8th, 2016
Starpharma to present at Bio-Europe® conference

Oct 2016
Oct 28th, 2016
Appendix 4C - Quarterly Cashflow Report
Oct 28th, 2016
Additional Priostar Glyphosate Patent Allowed in US
Oct 26th, 2016
Notice of Annual General Meeting and Proxy Form
Oct 26th, 2016
Starpharma to present at US Drug Delivery Conference
Oct 25th, 2016
Starpharma to present at ASX Spotlight in Asia
Oct 17th, 2016
Change in Director's Interest Notice - R Thomas
Oct 13th, 2016
Enrolment complete for Phase 3 VivaGel BV-R program
Oct 13th, 2016
Appendix 3B
Oct 13th, 2016
Change in Director's Interest Notice - J Fairley
Oct 7th, 2016
Change in Director's Interest Notice - J Fairley
Oct 7th, 2016
Appendix 3B
Oct 3rd, 2016
Notification of AGM date

Sep 2016
Sep 19th, 2016
Change in Director's Interest Notice - R Thomas
Sep 14th, 2016
Change in substantial holding
Sep 13th, 2016
VivaGel® condom receives regulatory approval in Canada

Aug 2016
Aug 31st, 2016
Appendix 4E - Correction to NTA Backing
Aug 30th, 2016
Starpharma Highlights of FY2016 Presentation
Aug 29th, 2016
Appendix 4G - Corporate Governance Statement
Aug 29th, 2016
Annual report and full year financial results

Jul 2016
Jul 28th, 2016
Starpharma initiates new DEP™ drug delivery program with AstraZeneca
Jul 21st, 2016
Starpharma signs license for a VivaGel® condom in China
Jul 13th, 2016
Appendix 4C - Quarterly Cashflow Report

Jun 2016
Jun 14th, 2016
Change in substantial holding

May 2016
May 25th, 2016
Starpharma's DEP eliminates cabazitaxel neutropenia
May 19th, 2016
Change in Director's Interest Notice - R Thomas
May 17th, 2016
Starpharma to present at ASX CEO Session
May 16th, 2016
Australian Olympic Team taking Dual Protect™ VivaGel® Condoms to Rio
May 5th, 2016
VivaGel active against Zika virus

Apr 2016
Apr 28th, 2016
Appendix 4C - Quarterly Cashflow Report
Apr 13th, 2016
Shareholder Update April 2016
Apr 5th, 2016
Starpharma to present at Bio-Europe conference
Apr 4th, 2016
DEP cabazitaxel shows complete and sustained tumour regression

Mar 2016
Mar 17th, 2016
Adama Licenses Starpharma's Priostar for Novel 2,4-D
Mar 4th, 2016
Starpharma licences VivaGel BV to Aspen for ANZ

Feb 2016
Feb 24th, 2016
Change in substantial holding
Feb 17th, 2016
Interim Report and Half-Year Financial Results
Feb 2nd, 2016
Targeted DEP shows sustained superior performance

Jan 2016
Jan 28th, 2016
Appendix 4C - Quarterly Cashflow Report
Jan 27th, 2016
Change in Director's Interest Notice - R Thomas
Jan 27th, 2016
Change in Director's Interest Notice - J Fairley
Jan 27th, 2016
Change in Director's Interest Notice - P Turvey
Jan 27th, 2016
Change in Director's Interest Notice - Z Peach
Jan 25th, 2016
Appendix 3B
Jan 22nd, 2016
Appendix 3B - SPP
Jan 20th, 2016
Starpharma raises $1.9M under Share Purchase Plan

Dec 2015
Dec 22nd, 2015
Change in Director's Interest Notice - R Thomas
Dec 18th, 2015
Change in substantial holding
Dec 16th, 2015
Starpharma signs MOU for VivaGel condom in China
Dec 16th, 2015
Cleansing Statement
Dec 16th, 2015
Appendix 3B - Share Placement
Dec 16th, 2015
Share Purchase Plan Offer Documents
Dec 15th, 2015
Change in substantial holding
Dec 9th, 2015
Starpharma completes A$32 million placement - SPP to follow
Dec 7th, 2015
Trading halt
Dec 4th, 2015
Appendix 3B
Dec 4th, 2015
Change in Director's Interest Notice - J Fairley
Dec 2nd, 2015
Second DEP™ candidate selected by AstraZeneca

Nov 2015
Nov 19th, 2015
Retirement of Director Peter Jenkins and Appendix 3Z
Nov 19th, 2015
AGM - Chair address and CEO presentation
Nov 19th, 2015
2015 AGM results
Nov 16th, 2015
Targeted DEP outperforms leading treatments in ovarian cancer model
Nov 12th, 2015
Starpharma receives $3.4M R&D tax incentive refund
Nov 4th, 2015
Starpharma to present at BioEurope conference

Oct 2015
Oct 30th, 2015
Appendix 4C - Quarterly Cashflow Report
Oct 29th, 2015
Shareholder Update October 2015
Oct 16th, 2015
Notice of Annual General Meeting/Proxy Form
Oct 14th, 2015
Additional US Patent Granted for VivaGel BV
Oct 9th, 2015
Change in Director's Interest Notice - J Fairley
Oct 9th, 2015
Appendix 3B
Oct 1st, 2015
OTCQX Life Sciences Presentation

Sep 2015
Sep 28th, 2015
Change in Director's Interest Notice - R Thomas
Sep 28th, 2015
Appendix 3B
Sep 24th, 2015
EU Marketing Approval Granted for VivaGel BV
Sep 21st, 2015
Change in Director's Interest Notice - R Hazleton
Sep 21st, 2015
Date of Annual General Meeting
Sep 10th, 2015
Change in Director's Interest Notice - P Turvey
Sep 9th, 2015
Change in Director's Interest Notice - Z Peach
Sep 9th, 2015
Change in Director's Interest Notice - J Fairley
Sep 9th, 2015
Change in Director's Interest Notice - R Thomas
Sep 7th, 2015
Drug delivery license with AstraZeneca - Investor conference call
Sep 7th, 2015
Starpharma signs drug delivery license with AstraZeneca

Aug 2015
Aug 21st, 2015
Appendix 4G - Corporate Governance Statement
Aug 21st, 2015
Annual Report and full year financial results

Jul 2015
Jul 30th, 2015
Appendix 4C - Quarterly Cashflow Report
Jul 1st, 2015
Change in substantial holding

Jun 2015
Jun 10th, 2015
Notice of Initial Substantial Holder

May 2015
May 27th, 2015
Change in Director's Interest Notice - J Fairley
May 8th, 2015
Change in substantial holding
May 4th, 2015
AstraZeneca to develop oncology drug using SPL’s DEP™ technology
May 1st, 2015
Ceasing to be a Substantial Holder

Apr 2015
Apr 30th, 2015
DEP™ Docetaxel Trial Dose Exceeds Common Taxotere® Dose Level
Apr 30th, 2015
Appendix 4C - Quarterly Cashflow Report
Apr 22nd, 2015
Securities Dealing Policy

Mar 2015
Mar 23rd, 2015
Shareholder Update March 2015
Mar 5th, 2015
Starpharma to present at March US investor conferences

Feb 2015
Feb 17th, 2015
Starpharma presents at ASX Investor Series
Feb 16th, 2015
Interim Report and Half-Year Financial Results

Jan 2015
Jan 30th, 2015
Appendix 3B
Jan 28th, 2015
Appendix 4C - Quarterly Cashflow Report
Jan 22nd, 2015
Appendix 3B
Jan 12th, 2015
Starpharma to present at Biotech Showcase